Scalper1 News
Valeant Pharmaceuticals (VRX) stock fell early Thursday after the drugmaker said late Wednesday that it had received a federal subpoena over its drug-pricing policy. Valeant said it received subpoenas from the U.S. District Attorneys of Massachusetts and southern New York, which “relate to documents with respect to our patient assistance programs, and also include requests relating to financial support provided by the company for patients, Scalper1 News
Scalper1 News